Abstract
Yohimbine, a pharmacologically well-characterized α-2-adrenoceptor antagonist with activity in the central and peripheral nervous system, has been used for over a century in the treatment of erectile dysfunction. In-depth, systematic studies in animals have shown that the drug has a remarkable positive effect on sexual performance. Meta-analyses of the few controlled, randomized human studies have consistently shown an advantage of yohimbine over placebo. Despite such a long history and encouraging activity, the drug has not yet been subjected to scientifically rigorous human clinical trials. Although relevant basic pharmacological and animal research information has been available for over 15 y, recent studies were designed with a lack of insight and complete disregard of those fundamental studies. Currently, dose–response investigations are not available, alternative routes of administration (i.e. sublingual) have not been investigated, nor has continuous versus ‘on-demand’ administration been explored. Synergistic activity with other drugs was last studied nearly four decades ago. Assessment of various populations was carried out in very limited cohorts and only in most general terms. In short, properly designed trials in humans have not been done. Why? Yohimbine is an old drug. As such it does not enjoy patent protection or commercial viability. Until molecular/formulation changes can be brought about (as recently happened with two other agents: phentolamine and apomorphine), serious investigations of yohimbine will remain in limbo. It could be that the nay sayers are right and yohimbine, indeed, lacks clinical activity as a treatment for men with erectile dysfunction. As long as it remains an orphan drug, we will never know.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morales, A. Yohimbine in erectile dysfunction: the facts. Int J Impot Res 12 (Suppl 1), S70–S74 (2000). https://doi.org/10.1038/sj.ijir.3900508
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3900508
Keywords
This article is cited by
-
Mechanistic investigation into the binding property of Yohimbe towards natural polymeric DNAs
Scientific Reports (2023)
-
Heart Rate Variability and Erectile Function in Younger Men: A Pilot Study
Applied Psychophysiology and Biofeedback (2021)
-
Exploring new pharmacology and toxicological screening and safety evaluation of one widely used formulation of Nidrakar Bati from South Asia region
BMC Complementary and Alternative Medicine (2015)
-
Dietary supplement increases plasma norepinephrine, lipolysis, and metabolic rate in resistance trained men
Journal of the International Society of Sports Nutrition (2009)
-
Refractory priapism associated with ingestion of yohimbe extract
Journal of Medical Toxicology (2009)